Page 3 - Wendyk Chung News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Researchers Discover Unknown Childhood Genetic Condition and its Potential Cure
ucsd.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ucsd.edu Daily Mail and Mail on Sunday newspapers.
Teens knowing results of their cardiomyopathy genetic tests may improve family function
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BETHESDA, Md., May 20, 2021 /PRNewswire/ The American College of Medical Genetics and Genomics (ACMG) has just released an updated policy statement and gene list for the reporting of secondary findings (SF). Together, these two documents update the recommendations for SF reporting and unveil the highly anticipated recommended minimum gene list
(SF v3.0) for reporting secondary findings in clinical exome and genome sequencing. The ACMG also declares its intent to update the SF gene list now annually, with a goal of publishing the updated list each January.
Genetics in Medicine. Our group worked very hard on this update, taking a thoughtful and careful approach that balances the goals of keeping it as a minimum list while also providing results that will impact patients and their families in a positive way, said lead author and co-chair of the ACMG SFWG, David T. Miller, MD, PhD, FACMG.
Published: Feb 19, 2021 By Alex Keown
PICI – Bristol Myers Squibb veteran Ute Dugan was named Senior Vice President of Clinical Research at the Parker Institute for Cancer Immunotherapy (PICI). She will oversee PICI’s clinical development, regulatory affairs and translational medicine efforts, with a focus on overcoming immunotherapy resistance and advancing novel breakthrough treatment combinations. At BMS, she was head of Worldwide Oncology External Medical Affairs, where she created research collaboration models to advance immune-oncology treatments together with partners in academia, professional societies and non-profit organizations. Dugan originally joined BMS as executive director of Global Clinical Research during the formation of the development teams for the pioneering I-O medicines ipilimumab and nivolumab. Before that, her career included stints at Roche/Genentech and Aventis.